LeMaitre Vascular (NASDAQ:LMAT) Rating Increased to Buy at Stifel Nicolaus

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) was upgraded by equities research analysts at Stifel Nicolaus from a "hold" rating to a "buy" rating in a report issued on Friday, MarketBeat Ratings reports. The brokerage currently has a $75.00 target price on the medical instruments supplier's stock, up from their previous target price of $59.00. Stifel Nicolaus' price target suggests a potential upside of 14.57% from the company's previous close.

Other research analysts also recently issued research reports about the stock. StockNews.com downgraded shares of LeMaitre Vascular from a "buy" rating to a "hold" rating in a research report on Tuesday, April 16th. KeyCorp assumed coverage on shares of LeMaitre Vascular in a research report on Tuesday, February 6th. They set a "sector weight" rating on the stock. Finally, Barrington Research boosted their target price on shares of LeMaitre Vascular from $66.00 to $69.00 and gave the stock an "outperform" rating in a research report on Wednesday, February 28th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat, LeMaitre Vascular has a consensus rating of "Moderate Buy" and a consensus target price of $69.33.

LeMaitre Vascular Price Performance

Shares of NASDAQ:LMAT traded up $2.47 during trading hours on Friday, hitting $65.46. The company's stock had a trading volume of 117,291 shares, compared to its average volume of 111,857. LeMaitre Vascular has a 52 week low of $44.27 and a 52 week high of $74.64. The company has a market capitalization of $1.47 billion, a price-to-earnings ratio of 47.01, a P/E/G ratio of 2.76 and a beta of 0.87. The firm's fifty day moving average price is $65.30 and its 200 day moving average price is $58.05.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 27th. The medical instruments supplier reported $0.38 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.36 by $0.02. LeMaitre Vascular had a net margin of 15.56% and a return on equity of 10.57%. The firm had revenue of $48.90 million for the quarter, compared to the consensus estimate of $49.01 million. During the same quarter in the previous year, the firm earned $0.25 EPS. The company's quarterly revenue was up 19.3% compared to the same quarter last year. On average, equities research analysts predict that LeMaitre Vascular will post 1.66 earnings per share for the current fiscal year.

Insider Buying and Selling at LeMaitre Vascular

In other LeMaitre Vascular news, Director Lawrence J. Jasinski sold 5,110 shares of LeMaitre Vascular stock in a transaction that occurred on Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the sale, the director now directly owns 5,309 shares in the company, valued at approximately $358,357.50. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, CEO George W. Lemaitre sold 36,600 shares of the business's stock in a transaction on Monday, March 4th. The shares were sold at an average price of $68.03, for a total value of $2,489,898.00. Following the completion of the transaction, the chief executive officer now directly owns 2,187,526 shares in the company, valued at approximately $148,817,393.78. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Lawrence J. Jasinski sold 5,110 shares of the business's stock in a transaction on Tuesday, March 5th. The shares were sold at an average price of $67.50, for a total transaction of $344,925.00. Following the completion of the transaction, the director now owns 5,309 shares of the company's stock, valued at $358,357.50. The disclosure for this sale can be found here. In the last ninety days, insiders sold 114,036 shares of company stock worth $7,873,749. Company insiders own 10.79% of the company's stock.

Hedge Funds Weigh In On LeMaitre Vascular

Several large investors have recently made changes to their positions in LMAT. BluePath Capital Management LLC acquired a new position in shares of LeMaitre Vascular in the 3rd quarter valued at $31,000. YHB Investment Advisors Inc. acquired a new position in LeMaitre Vascular during the first quarter worth $36,000. DekaBank Deutsche Girozentrale acquired a new position in LeMaitre Vascular during the third quarter worth $38,000. SRS Capital Advisors Inc. raised its position in LeMaitre Vascular by 325.5% during the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 524 shares during the period. Finally, Albion Financial Group UT raised its position in LeMaitre Vascular by 5.6% during the first quarter. Albion Financial Group UT now owns 3,974 shares of the medical instruments supplier's stock worth $264,000 after acquiring an additional 212 shares during the period. 84.64% of the stock is currently owned by institutional investors and hedge funds.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.